#non-small-cell lung cancer

Personalized risk assessment identified 9% more lung cancer cases for screening compared with current U.S. guidelines.

Providers who treat smokers with lung cancer should offer support to help them quit.

Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.

Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.

The decrease is largely due to improved lung cancer treatment, but the impact of COVID-19 is not yet known.

In recent years, deaths from non-small cell lung cancer (NSCLC) have decreased even faster than the decrease in NSCLC incidence.

Selpercatinib, the first drug in its class, shrank tumors in over two thirds of previously treated patients.

A study out of China found cancer patients had a higher coronavirus risk, possibly because of hospital visits.

ASCO and Friends of Cancer Research proposed new eligibility guidelines in 2017.

Researchers believe specially designed cancer care programs could prevent Black patients from being lost to care.

Blacks have higher rates of positive screens and lung cancer diagnosis.